Zealand Pharma A/S (OTCMKTS:ZLDPF) Releases Earnings Results, Beats Expectations By $8.47 EPS

Zealand Pharma A/S (OTCMKTS:ZLDPF) posted its earnings results on Thursday. The company reported $8.61 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.14 by $8.47, Zacks reports. Zealand Pharma A/S had a net margin of 68.82% and a return on equity of 41.80%.

Zealand Pharma A/S Stock Performance

Shares of OTCMKTS ZLDPF traded up $0.88 during mid-day trading on Thursday, hitting $52.68. The company had a trading volume of 180 shares, compared to its average volume of 2,874. Zealand Pharma A/S has a 12 month low of $35.93 and a 12 month high of $83.12. The stock has a market cap of $3.77 billion, a price-to-earnings ratio of 3.91 and a beta of 0.88. The company has a debt-to-equity ratio of 0.02, a current ratio of 37.17 and a quick ratio of 37.17. The firm’s 50 day simple moving average is $45.56 and its two-hundred day simple moving average is $49.57.

Analyst Upgrades and Downgrades

ZLDPF has been the subject of several analyst reports. Berenberg Bank downgraded Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, June 17th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating on shares of Zealand Pharma A/S in a research note on Thursday, June 4th. Wolfe Research lowered shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a report on Thursday, June 11th. Finally, Jefferies Financial Group lowered shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 13th. One investment analyst has rated the stock with a Strong Buy rating and eight have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold”.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.